Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 8/3075% above fair value
$3.52−0.26 (-6.88%)
Close on Nov 12, 2026Market cap $280.91MP/E –Yield –
Prelude Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Prelude Therapeutics's enterprise value was $166.47M on Nov 11, 2026, against $72.72M a year earlier. Over the last 5 years it ranged from -$170.86M to $337.33M, with a median of $47.51M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $166.47M | +0.6% |
| 2025 | Dec 31, 2025 | $165.43M | – |
| 2024 | Dec 31, 2024 | -$58.97M | -1736.3% |
| 2023 | Dec 29, 2023 | $3.60M | -94.0% |
| 2022 | Dec 30, 2022 | $60.54M | – |
| 2021 | Jan 29, 2021 | -$89.76M | – |
| 2020 | Dec 31, 2020 | -$75.02M | – |
See a number that looks wrong?